Insilico Medicine has reached a significant clinical milestone with the completion of first-in-human dosing of ISM8969 in a Phase 1 study. Conducted in collaboration with Hygtia Therapeutics, the ISM8969 Phase 1 trial marks the transition of this oral, brain-penetrant NLRP3 inflammasome inhibitor from preclinical development into human evaluation. The compound is designed to address chronic neuroinflammation and central nervous system disorders, including Parkinson’s disease, by directly targeting inflammatory pathways within the brain.
First-in-Human Dosing Launches in Australia
The Phase 1 study is structured as a randomized, double-blind, placebo-controlled trial encompassing both single ascending dose and multiple ascending dose cohorts. A total of 100 participants are planned for enrollment, including healthy volunteers and obese adults with cardiovascular risk factors. The trial, based in Australia, will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ISM8969. Notably, researchers will also collect cerebrospinal fluid samples during the study. These samples are intended to assess the degree of CNS penetration and target engagement achieved by the molecule, data that will be critical for guiding dose selection in subsequent trials and supporting future therapeutic validation in neurodegenerative disease programs.
ISM8969 targets the NLRP3 inflammasome, a central regulator of the innate immune system. When overactivated, the NLRP3 inflammasome drives chronic inflammation and cytokine release, processes closely linked to neurodegeneration and tissue damage in conditions such as Parkinson’s disease. What sets ISM8969 apart from other NLRP3 inhibitor candidates currently in development is its design as a brain-penetrant small molecule. While many existing inhibitors remain peripherally restricted, ISM8969 is engineered to cross the blood-brain barrier and directly modulate neuroinflammation within the central nervous system. This capability opens the door to broader neurological disease applications beyond those reachable by peripheral-only compounds.
In preclinical studies, ISM8969 demonstrated strong in vitro activity alongside a favorable safety profile. The molecule showed consistent in vivo pharmacokinetics and pharmacodynamics across multiple inflammatory disease models, including both acute and chronic preclinical systems. ISM8969 was selected as a preclinical candidate in December 2024, setting the stage for its rapid advancement into human testing.
AI-Driven Discovery Accelerates the Path to Clinic
“Advancing ISM8969 from an AI-generated concept to first-in-human dosing is a major step forward, as well as the first clinical milestone in our collaboration with Hygtia Therapeutics,” said Feng Ren, PhD, Co-CEO and Chief Scientific Officer of Insilico Medicine. “Developing an effective NLRP3 inhibitor that can safely penetrate the blood-brain barrier has long been a challenge for the industry. Leveraging Chemistry42, we precisely optimized the molecule to deliver strong preclinical efficacy and favorable permeability. We look forward to evaluating its translational potential in this Phase 1 trial and to continuing our close collaboration with Hygtia to advance innovative neuroscience therapies for patients worldwide.”
Under the terms of their exclusive global co-development partnership, Insilico Medicine and Hygtia Therapeutics hold equal global rights at fifty percent each. Insilico is responsible for leading the IND submission and Phase 1 execution for the ISM8969 Phase 1 trial program, which may generate up to sixty-six million dollars in milestone payments.
Insilico Medicine continues to expand its AI-driven drug discovery platform, which has compressed preclinical timelines to as few as 12 to 18 months while reducing synthesis requirements to under 200 molecules per program. Since 2021, the company has nominated 31 preclinical candidates, thirteen of which have already achieved IND approval or clearance. Additionally, Insilico is advancing its MMAI Gym platform for AI benchmarking, a system designed to support domain-specific scientific model training and evaluate real-world pharmaceutical reasoning performance. Partners in this initiative include Human Longevity and Liquid AI, with the platform aimed at accelerating progress toward what the company describes as pharma superintelligence.
